Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • BI 2536 - Pancreatic Neoplasms
    Clinical Study Number 1216.8
    Study Indication Pancreatic Neoplasms
    Product BI 2536
    Generic Name BI 2536
    Lab Code
    Clinical Phase I
    Study Title

    A Phase I open-label dose-finding study of intravenous BI 2536 administered inrepeated 4-week cycles as repeated doses on Day 1 and Day 15 in combinationwith gemcitabine administered on Day 1, Day 8 and Day 15 in patients withlocally advanced or metastatic pancreatic cancer

    Study Document
    Trial synopsis 1216.8_CO english
  • BI 2536 - Pancreatic Neoplasms
    Clinical Study Number 1216.10
    Study Indication Pancreatic Neoplasms
    Product BI 2536
    Generic Name BI 2536
    Lab Code
    Clinical Phase II
    Study Title

    An open, randomised, clinical phase II trial in patients with unresectable advanced pancreatic cancer investigating the efficacy, safety, and pharmacokinetics of BI 2536 administered in repeated 3-week cycles as a single IV dose of 200 mg on Day 1 or as 60 mg doses on Days 1, 2, and 3

    Study Document
    Trial synopsis 1216.10 english